PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Antimicrobial Susceptibility of Staphylococcus aureus to Anti-inflammatory Drugs With a Focus on the Combinatory Effect of Celecoxib With Oxacillin In Vitro
Version 1
: Received: 21 November 2023 / Approved: 22 November 2023 / Online: 22 November 2023 (06:33:47 CET)
How to cite:
Okpala, O. E.; Rondevaldova, J.; Osei-Owusu, H.; Kudera, T.; Kokoska, L. Antimicrobial Susceptibility of Staphylococcus aureus to Anti-inflammatory Drugs With a Focus on the Combinatory Effect of Celecoxib With Oxacillin In Vitro. Preprints2023, 2023111379. https://doi.org/10.20944/preprints202311.1379.v1
Okpala, O. E.; Rondevaldova, J.; Osei-Owusu, H.; Kudera, T.; Kokoska, L. Antimicrobial Susceptibility of Staphylococcus aureus to Anti-inflammatory Drugs With a Focus on the Combinatory Effect of Celecoxib With Oxacillin In Vitro. Preprints 2023, 2023111379. https://doi.org/10.20944/preprints202311.1379.v1
Okpala, O. E.; Rondevaldova, J.; Osei-Owusu, H.; Kudera, T.; Kokoska, L. Antimicrobial Susceptibility of Staphylococcus aureus to Anti-inflammatory Drugs With a Focus on the Combinatory Effect of Celecoxib With Oxacillin In Vitro. Preprints2023, 2023111379. https://doi.org/10.20944/preprints202311.1379.v1
APA Style
Okpala, O. E., Rondevaldova, J., Osei-Owusu, H., Kudera, T., & Kokoska, L. (2023). Antimicrobial Susceptibility of <em>Staphylococcus aureus</em> to Anti-inflammatory Drugs With a Focus on the Combinatory Effect of Celecoxib With Oxacillin In Vitro. Preprints. https://doi.org/10.20944/preprints202311.1379.v1
Chicago/Turabian Style
Okpala, O. E., Tomas Kudera and Ladislav Kokoska. 2023 "Antimicrobial Susceptibility of <em>Staphylococcus aureus</em> to Anti-inflammatory Drugs With a Focus on the Combinatory Effect of Celecoxib With Oxacillin In Vitro" Preprints. https://doi.org/10.20944/preprints202311.1379.v1
Abstract
Musculoskeletal infections (MIs) are among the most difficult-to-treat staphylococcal diseases. The limited availability of effective antibiotics has encouraged the development of innovative strategies such as combinatory therapy to combat MI. The aim of this study was to investigate the in vitro antistaphylococcal activity of anti-inflammatory and the antimicrobial combinatory effect of celecoxib with oxacillin. The minimum inhibitory concentrations (MICs) of 17 anti-inflammatory drugs were determined for standard strains and clinical isolates of S. aureus strains, counting methicillin-resistant strains (MRSA), by the broth microdilution method. The fractional inhibitory concentration indices (FICIs) were evaluated by the checkerboard assays. Celecoxib produced the most potent antistaphylococcal effect against all the tested strains (MIC ranging from 32 to 64 mg/mL), followed by diacerein against MRSA3 and MRSA ATCC 33592 (MIC 64 mg/mL). Several synergistic effects were observed for tested S. aureus strains, including MRSA (FICI ranging from 0.087 to 0.471). The strongest synergistic interaction (FICI 0.087) was obtained against MRSA ATCC 33592 at a celecoxib concentration of 2 mg/mL with a 19-fold oxacillin MIC reduction (from 512 to 26.888 mg/mL). This is the first report on the antistaphylococcal combinatory effect of celecoxib with oxacillin. Our findings suggest celecoxib and its combination with oxacillin as perspective agents for research focused on the development of novel therapies for MI caused by S. aureus. Thus, this study presents novel findings that celecoxib could, in some cases, resensitise MRSA strains to become susceptible to certain β-lactams (e.g., oxacillin) not previously tested.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
*
